Ascendis Pharma Bone Diseases A/S
3 clinical trials · Sponsor
◉ Watch Ascendis Pharma Bone Diseases A/S
| Record | Firm | Date |
|---|---|---|
| A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism (NCT07081997) | Ascendis Pharma Bone Diseases A/S | 2026-05-07 |
Track Ascendis Pharma Bone Diseases A/S automatically
Every clearance here is in the API, with alerts when new ones post.